Literature DB >> 25242213

The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.

Xingmin Sun1, Simon A Hirota2.   

Abstract

Clostridium difficile (C. difficile) is the most common cause of nosocomial antibiotic-associated diarrhea and the etiologic agent of pseudomembranous colitis. The clinical manifestation of C. difficile infection (CDI) is highly variable, from asymptomatic carriage, to mild self-limiting diarrhea, to the more severe pseudomembranous colitis. Furthermore, in extreme cases, colonic inflammation and tissue damage can lead to toxic megacolon, a condition requiring surgical intervention. C. difficile expresses two key virulence factors; the exotoxins, toxin A (TcdA) and toxin B (TcdB), which are glucosyltransferases that target host-cell monomeric GTPases. In addition, some hypervirulent strains produce a third toxin, binary toxin or C. difficile transferase (CDT), which may contribute to the pathogenesis of CDI. More recently, other factors such as surface layer proteins (SLPs) and flagellin have also been linked to the inflammatory responses observed in CDI. Although the adaptive immune response can influence the severity of CDI, the innate immune responses to C. difficile and its toxins play crucial roles in CDI onset, progression, and overall prognosis. Despite this, the innate immune responses in CDI have drawn relatively little attention from clinical researchers. Targeting these responses may prove useful clinically as adjuvant therapies, especially in refractory and/or recurrent CDI. This review will focus on recent advances in our understanding of how C. difficile and its toxins modulate innate immune responses that contribute to CDI pathogenesis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile infection; Innate immune response; Pathogenesis; Virulence factors

Mesh:

Substances:

Year:  2014        PMID: 25242213      PMCID: PMC4254213          DOI: 10.1016/j.molimm.2014.09.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  158 in total

1.  Trans-10, cis-12 conjugated linoleic acid modulates phagocytic responses of canine peripheral blood polymorphonuclear neutrophilic leukocytes exposed to Clostridium difficile toxin B.

Authors:  Ji-Houn Kang; Geun-Shik Lee; Eui-Bae Jeung; Mhan-Pyo Yang
Journal:  Vet Immunol Immunopathol       Date:  2009-02-13       Impact factor: 2.046

2.  Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B.

Authors:  Selda Genisyuerek; Panagiotis Papatheodorou; Gregor Guttenberg; Rolf Schubert; Roland Benz; Klaus Aktories
Journal:  Mol Microbiol       Date:  2011-01-28       Impact factor: 3.501

3.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

4.  Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen.

Authors:  Mizuho Hasegawa; Takashi Yamazaki; Nobuhiko Kamada; Kazuki Tawaratsumida; Yun-Gi Kim; Gabriel Núñez; Naohiro Inohara
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

5.  Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes.

Authors:  Xi Na; Dezheng Zhao; Hon Wai Koon; Ho Kim; Johanna Husmark; Mary P Moyer; Charalabos Pothoulakis; J Thomas LaMont
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

6.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Human alpha-defensins inhibit Clostridium difficile toxin B.

Authors:  Torsten Giesemann; Gregor Guttenberg; Klaus Aktories
Journal:  Gastroenterology       Date:  2008-03-10       Impact factor: 22.682

8.  Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins.

Authors:  Claire Janoir; Séverine Péchiné; Charlotte Grosdidier; Anne Collignon
Journal:  J Bacteriol       Date:  2007-08-10       Impact factor: 3.490

9.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

10.  Binary toxin and death after Clostridium difficile infection.

Authors:  Sabrina Bacci; Kåre Mølbak; Marianne K Kjeldsen; Katharina E P Olsen
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

View more
  32 in total

Review 1.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  Loss of Interleukin-10 (IL-10) Signaling Promotes IL-22-Dependent Host Defenses against Acute Clostridioides difficile Infection.

Authors:  Emily S Cribas; Joshua E Denny; Jeffrey R Maslanka; Michael C Abt
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

3.  Clostridium difficile toxins A and B decrease intestinal SLC26A3 protein expression.

Authors:  Hayley Coffing; Shubha Priyamvada; Arivarasu N Anbazhagan; Christine Salibay; Melinda Engevik; James Versalovic; Mary Beth Yacyshyn; Bruce Yacyshyn; Sangeeta Tyagi; Seema Saksena; Ravinder K Gill; Waddah A Alrefai; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-29       Impact factor: 4.052

Review 4.  Clostridium difficile infection.

Authors:  Wiep Klaas Smits; Dena Lyras; D Borden Lacy; Mark H Wilcox; Ed J Kuijper
Journal:  Nat Rev Dis Primers       Date:  2016-04-07       Impact factor: 52.329

Review 5.  Secretory diarrhoea: mechanisms and emerging therapies.

Authors:  Jay R Thiagarajah; Mark Donowitz; Alan S Verkman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-30       Impact factor: 46.802

Review 6.  The role of toxins in Clostridium difficile infection.

Authors:  Ramyavardhanee Chandrasekaran; D Borden Lacy
Journal:  FEMS Microbiol Rev       Date:  2017-11-01       Impact factor: 16.408

7.  Exploiting a host-commensal interaction to promote intestinal barrier function and enteric pathogen tolerance.

Authors:  Virginia A Pedicord; Ainsley A K Lockhart; Kavita J Rangan; Jeffrey W Craig; Jakob Loschko; Aneta Rogoz; Howard C Hang; Daniel Mucida
Journal:  Sci Immunol       Date:  2016-09-22

8.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

Review 9.  Host response to Clostridium difficile infection: Diagnostics and detection.

Authors:  Elena A Usacheva; Jian-P Jin; Lance R Peterson
Journal:  J Glob Antimicrob Resist       Date:  2016-09-20       Impact factor: 4.035

10.  Faecalibacterium prausnitzii and a Prebiotic Protect Intestinal Health in a Mouse Model of Antibiotic and Clostridium difficile Exposure.

Authors:  Sanjoy Roychowdhury; Jennifer Cadnum; Bryan Glueck; Mark Obrenovich; Curtis Donskey; Gail A M Cresci
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-01-31       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.